TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06250452

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Halotherapy (Salt Therapy)
Description: Personal Information Form, SPO2 measurement and Asthma Symptom and Treatment Need Scoring / Daily Follow-up Form will be applied to the children in the experimental group before they are taken to the salt therapy room. Scales and SPO2 measurement will be performed before, during and after therapy. The same procedure will be applied to the children in the control group, but no therapy will be applied. In the study planned to be carried out for 6 weeks, it is recommended that children repeat the session for 10 minutes daily, the first 5 sessions every day and the other 5 weeks once a week.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Halotherapy (Salt Therapy)
Description: Personal Information Form, SPO2 measurement and Asthma Symptom and Treatment Need Scoring / Daily Follow-up Form will be applied to the children in the experimental group before they are taken to the salt therapy room. Scales and SPO2 measurement will be performed before, during and after therapy. The same procedure will be applied to the children in the control group, but no therapy will be applied. In the study planned to be carried out for 6 weeks, it is recommended that children repeat the session for 10 minutes daily, the first 5 sessions every day and the other 5 weeks once a week.
Study: NCT05631730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flecainide
Description: Flecainide is mainly used for pharmacological conversion in patients with atrial tachyarrhythmias and to suppress ventricular arrhythmias in patients with structurally normal hearts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Metoprolol is a beta-blocker and class II antiarrhythmic drug considered standard care in most cardiac diseases predisposing to ventricular arrhythmias, including arrhythmic mitral valve prolapse.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Metoprolol is a beta-blocker and class II antiarrhythmic drug considered standard care in most cardiac diseases predisposing to ventricular arrhythmias, including arrhythmic mitral valve prolapse.
Study: NCT04802759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH FDC SC
Description: On Day 1 of Cycle 1 (1 cycle is 21 days), pertuzumab and trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) will be administered SC as a fixed dose formulation of 1200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase. On Day 1 of Cycles 2 and beyond, PH FDC SC will be administered SC once every 21 days as a fixed dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH FDC SC
Description: On Day 1 of Cycle 1 (1 cycle is 21 days), pertuzumab and trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) will be administered SC as a fixed dose formulation of 1200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase. On Day 1 of Cycles 2 and beyond, PH FDC SC will be administered SC once every 21 days as a fixed dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: 125 mg orally once a day on Days 1-21 during each 28-day cycle until unacceptable toxicity or disease progression
Study: NCT06014476

Intervention type: OTHER
Intervention: questionnaires
Description: Sent questionnaires to caregivers and used CRS-R to assess patients with DoC

Intervention type: OTHER
Intervention: questionnaires
Description: Sent questionnaires to caregivers and used CRS-R to assess patients with DoC
Study: NCT04875195

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, 400 mg, Q6W, intravenous (IV) infusion.
Study: NCT05707520

Intervention type: DRUG
Intervention: enteric-coated mycophenolate (MPAs)
Description: Immunosuppression protocol with enteric-coated mycophenolate sodium

Intervention type: DRUG
Intervention: None MPA
Description: Immunosuppression protocol without enteric-coated mycophenolate sodium
Study: NCT04802759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 840 mg by intravenous (IV) infusion on Days 1 and 15 each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 840 mg by intravenous (IV) infusion on Days 1 and 15 each 28-day cycle.
Study: NCT06331182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Patients will receive external oblique intercostal plane block using 29 ml bupivacaine 0.25% + 1 ml ketamine (50 mg) after induction of general anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients will receive external oblique intercostal plane block using 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 μg/kg after induction of general anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 29 ml bupivacaine 0.25%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 29 ml bupivacaine 0.25%
Study: NCT05937152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: Intravenous (IV) infusion of 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: Intravenous (IV) infusion of 300 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous (IV) infusion of placebo (looks exactly like the study drug, but it contains no active ingredients)
Study: NCT05611034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin infusion in single lung via IVLP technique
Study: NCT06065319

Intervention type: DEVICE
Intervention: Wearable Sensors
Description: Participants will wear smartwatches and smartrings and this data will be used to design algorithms which seek to find associations between device data and recovery.
Study: NCT05480189

Intervention type: OTHER
Intervention: Non-intervention
Description: Non-intervention,with real world study
Study: NCT06289920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR3005
Description: One tablet administered alone, Once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR3005-1
Description: One tablet administered alone, Once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR3005-2
Description: One tablet administered alone, Once a day
Study: NCT06200233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoceranib
Description: 700mg once daily
Study: NCT02969512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIPPER
Description: Participants can complete the online educational modules at home or another location with internet access. The total time to complete all of the modules is about 2 hours and 30 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OASIS Online Educational Webinars
Description: 2-hour online educational large group sessions
Study: NCT06538337

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam Radiotherapy
Description: Five fractions of radiation therapy using adaptive planning and CT or MRI guidance (6 Gy per fraction) delivered once every other day excluding weekends and holidays
Study: NCT05973981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Package standardization
Description: Conditions vary in terms of amount of cigarette packages that are subject to standardization

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Package standardization
Description: Conditions vary in terms of amount of cigarette packages that are subject to standardization

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Package standardization
Description: Conditions vary in terms of amount of cigarette packages that are subject to standardization
Study: NCT05643521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary composition of macronutrients and calories
Description: Carbohydrate restriction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary composition of macronutrients and calories
Description: Carbohydrate restriction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary composition of macronutrients and calories
Description: Carbohydrate restriction
Study: NCT05465668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001 Drug A
Description: DWP16001 Drug A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001 Drug C
Description: DWP16001 Drug C
Study: NCT05576415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Tartrate Nasal Spray
Description: Intranasal delivery of OC-01 (varenicline solution) 0.6 mg/mL twice a day (BID) for 28 days.
Study: NCT06352502

Intervention type: DRUG
Intervention: Furmonertinib
Description: Patients treated with Furmonertinib mesilate tablets orally
Study: NCT05781334

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Consult Intervention
Description: The intervention will consist of a quality improvement (QI)-based virtual consult designed by a multi-disciplinary team that will aim to address provider-level, patient-level, and system-level barriers to cardio-renal-metabolic disease medications
Study: NCT05297552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: Drug: RC48-ADC 2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001
Description: Drug: JS001 3.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
Study: NCT05594667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 25mg of psilocybin provided by Filament Health
Study: NCT05281549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Alteplase 0.9mg/kg are being used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: Tenecteplase 0.25mg/kg are being used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: Tenecteplase 0.4mg/kg are being used.
Study: NCT05981755

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing tasks
Description: Breathing tasks include normal breathing through nose or mouth, breathing while resting wakefully, increase and decrease in breathing rate, and breath counting.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain mapping with stimulation
Description: Electrical stimulation will be used to find specific areas of the brain involved in breathing function. Stimulation will be applied using a Nihon Kohden MEE-1000A neural function measuring system with the MS-120BK extension unit for brain stimulation.
Study: NCT04921969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: The study cream will be applied topically twice a day for up to 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: The study cream will be applied topically twice a day for up to 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Matching vehicle cream will be applied topically twice a day for up to 8 weeks.
Study: NCT05190757

Intervention type: OTHER
Intervention: Airway and Ventilation
Description: Insertion of Laryngeal Mask airway for ventilation or use of Face Mask

Intervention type: OTHER
Intervention: Airway and Ventilation
Description: Insertion of Laryngeal Mask airway for ventilation or use of Face Mask
Study: NCT06281665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Description: The intervention group will receive low-dose \[81 mg\] aspirin pill daily for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group will receive similar appearing placebo daily for 6 months.
Study: NCT04101851

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: omission of SLNB
Description: After radiologic complete remission at the end of NAST all patients will be treated with breast-conserving surgery alone without any axillary surgery.
Study: NCT06414148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Epcoritamab will be administered as a 28-day cycle. In Cycle 1 and 2, epcoritamab will be given with step up dosing in Cycle 1. From Cycle 3 onwards dosing will be on Day 1 and 15 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab, lenalidomide and rituximab
Description: Treatment with epcoritamab will be administered following the same dosing schedule as Arm A. On days where rituximab and/or lenalidomide are also due, epcoritamab should be administered last.~Patients will receive lenalidomide once daily on Day 1-21 of each 28-day cycle, starting at Cycle 1 through to Cycle 6.~Patients will receive rituximab administered by intravenous (IV) infusion on Day 1, 8, 15 and 22 of Cycle 1 and on Day 1 only of Cycles 2-6.
Study: NCT06340854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin icodec
Description: Insulin Icodec will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Insulin Icodec will be administered subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Insulin glargine will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Insulin glargine will be administered subcutaneously.
Study: NCT05970133

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colectomy with NOSE procedure
Description: The specimen will be extract from the anus.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colectomy with NOSE procedure
Description: The specimen will be extract from the anus.
Study: NCT06228066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Lurbinectedin is administered IV over 1 hour at 3.2 mg/m2 on day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Lurbinectedin is administered IV over 1 hour at 3.2 mg/m2 on day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab is administered IV at 800 mg over 1 hour on day 1 of each 21-day cycle
Study: NCT06474507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calculus bovis sativus (CBS)
Description: Subjects will orally receive 100mg CBS per day from day 1 to day 84.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calculus bovis sativus (CBS)
Description: Subjects will orally receive 100mg CBS per day from day 1 to day 84.
Study: NCT05892003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase 1 Control
Description: Control diet (30% Fat, 15% Protein, 55% Carbohydrate, Fibre rising from 10 to 16g/d). Fed to energy balance (1.5 x Resting Metabolic Rate, RMR).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase 2 High Fibre Weight Loss
Description: High Fibre Weight Loss diet (30% Fat, 15% Protein, 55% Carbohydrate). Fed to energy deficit (100% RMR). The quantity of fructo-oligosaccharides (FOS) will be fixed at 20g/day for all kcal levels with additional fibre coming from the diet provided. The FOS will be split over breakfast, lunch and dinner in drinks/yoghurts which will be compulsory to consume.
Study: NCT05714852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy eating
Description: Promotion of healthy eating
Study: NCT04058795

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer Distress Coach (CaDC) App
Description: an app that provides participants with tools to manage their stress in the moment they experience it.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CaDC + mCoaching
Description: The CaDC app plus weekly clinician support which provides support in navigating the app, encouraging adherence to the use of the CaDC, and providing guidance in choosing treatment strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mCBT
Description: 8 mobile sessions with a therapist to receive cognitive behavioral therapy.
Study: NCT05518214

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot
Description: Participants receive a 12-week supply of beetroot juice.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive a 12-week supply of placebo beetroot juice.
Study: NCT04989140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone
Description: Treatment was continued until disease progression, unacceptable toxicity
Study: NCT05892003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase 3 High Fibre and Non-Nutritive Sweetener Weight Loss
Description: High Fibre and Non-Nutritive Sweetener Weight Loss diet (30% Fat, 15% Protein, 55% Carbohydrate). Fed to energy deficit (100% RMR). The quantity of fructo-oligosaccharides (FOS) and non-nutritive sweetener (sucralose) will be fixed at 20g/day and 30mg/day respectively for all kcal levels with additional fibre coming from the diet provided. The FOS and sucralose will be split over breakfast, lunch and dinner in drinks/yoghurts which will be compulsory to consume.
Study: NCT04686084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual-energy computed tomography scan
Description: Diagnostic CT scan
Study: NCT05116111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA1402 tablets
Description: SYHA1402 tablets, oral, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA1402 tablets
Description: SYHA1402 tablets, oral, twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, oral, twice daily
Study: NCT05260450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1064 nm Nd:YAG-laser therapy
Description: All interventions and mycological tests for each subject were performed over the course of one day.~After subjects were included, toenails with a clinical suspicion of OM were tested for fungal infection by culture and microscopy. At the same time, nail clippings from said toenails were obtained and randomised into one of two treatment groups, i.e., group A and group B.~The nail clippings were then treated with a 1064 nm Nd:YAG-laser with laser settings as specified by the treatment groups. All nail clippings were treated only once.~Immediately after treatment, nail clippings were again tested for fungal infection by culture and microscopy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1064 nm Nd:YAG-laser therapy
Description: All interventions and mycological tests for each subject were performed over the course of one day.~After subjects were included, toenails with a clinical suspicion of OM were tested for fungal infection by culture and microscopy. At the same time, nail clippings from said toenails were obtained and randomised into one of two treatment groups, i.e., group A and group B.~The nail clippings were then treated with a 1064 nm Nd:YAG-laser with laser settings as specified by the treatment groups. All nail clippings were treated only once.~Immediately after treatment, nail clippings were again tested for fungal infection by culture and microscopy.
Study: NCT05256199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention
Description: A multidomain lifestyle intervention, including (1) physical activity, (2) cognitive training, (3) cardiovascular risk factor management (Cardiovascular), (4) dietary counselling, (5) Souvenaid, (6) sleep counselling, (7) stress management, and (8) social activities.
Study: NCT06110858

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tinkering Activities
Description: Tinkering activities encompass elements of science, art and technology. They emphasize that learning is not simply about teachers imparting knowledge to students, but rather about students actively constructing knowledge themselves. Tinkering activities are characterized by three key elements: active engagement, open-ended exploration and problem-solving. In such activities, participants are provided with products without telling the steps. They are then encouraged to attempt creating it on their own. During this hands-on learning process, participants need to flexibly change their mindset, think outside the box and tackle emerging problems, which challenge their executive functions.
Study: NCT06047548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study: NCT05004909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.05% Tretinoin
Description: Topical 0.05% tretinoin cream applied daily every night by the subjects according to assigned randomization
Study: NCT04411225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol oral solution
Description: Both the active drug (cannabidiol) and placebo will be in oral solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabidiol oral solution
Description: Both the active drug (cannabidiol) and placebo will be in oral solution.
Study: NCT05692206

Intervention type: OTHER
Intervention: evaluation
Description: Surveys will be administered to the participants. Participants will be given a stroop TBAG test.

Intervention type: OTHER
Intervention: evaluation
Description: Surveys will be administered to the participants. Participants will be given a stroop TBAG test.
Study: NCT06376812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: Physical activity
Study: NCT05246228

Intervention type: OTHER
Intervention: Peripheral blood sampling in order to evaluate changes in the circulating immune population
Description: Eveluation: circulating T cells CD3+CD8+ and CD3+CD4+, absolute lymphocyte count (ALC) and neutrophil counts (ANC) and neutrophil/lymphocyte ratio (NLR), Treg lymphocytes, Naïve/Memory T lymphocytes CD4+ and CD8+,myeloid-derived suppressor cells, Plasmacytoid Dendritic Cells NK cells dimension and bright, NKT cells, Myeloid Dendritic cells, Monocytes subsets, B lymphocytes ,Analysis of plasma cytokines (TNFalpha, TGFbeta, IL-6, IL-10) by ELISA,FN signature: real-time PCR on mRNA from peripheral blood mononuclear cells (PBMCs)
Study: NCT06047548

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT05678179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Patients will participate in standard clinical practice for bariatric surgery preparation with 50% of visits occurring via telehealth.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In Person (Face-2-Face)
Description: Patients will participate in standard clinical practice for bariatric surgery preparation with face-2-face clinic visits.